Several other analysts have also recently issued reports on GERN. B. Riley boosted their price objective on shares of Geron from $3.25 to $4.50 and gave the company a buy rating in a research note on Friday, June 28th. BidaskClub cut shares of Geron from a hold rating to a sell rating in a research note on Thursday, June 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. Geron presently has an average rating of Buy and an average target price of $3.33.
GERN stock opened at $1.32 on Friday. The stock has a market cap of $248.72 million, a PE ratio of -8.25 and a beta of 2.59. Geron has a one year low of $0.95 and a one year high of $6.99. The stock has a 50 day moving average price of $1.30.
Several hedge funds and other institutional investors have recently made changes to their positions in GERN. Amalgamated Bank purchased a new stake in shares of Geron during the 4th quarter valued at $25,000. Rudd International Inc. purchased a new stake in shares of Geron during the 2nd quarter valued at $30,000. Tower Research Capital LLC TRC grew its stake in shares of Geron by 482.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 29,801 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 24,684 shares during the period. BNP Paribas Arbitrage SA boosted its position in Geron by 6,429.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 36,629 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 36,068 shares during the period. Finally, DekaBank Deutsche Girozentrale boosted its position in Geron by 64.0% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 41,000 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 16,000 shares during the period. 31.06% of the stock is owned by institutional investors.
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.
Recommended Story: Preferred Stock
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.